Cargando…

Percutaneous autologous bone marrow concentrate for knee osteoarthritis: patient-reported outcomes and progenitor cell content

PURPOSE: Knee osteoarthritis (OA) is a common, progressively debilitating joint disease, and the intra-articular injection of autologous bone marrow concentrate (BMC) may offer a minimally invasive method of harnessing the body’s own connective tissue progenitor cells to counteract accompanying dege...

Descripción completa

Detalles Bibliográficos
Autores principales: Centeno, Christopher J., Berger, Dustin R., Money, Brandon T., Dodson, Ehren, Urbanek, Christopher W., Steinmetz, Neven J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492580/
https://www.ncbi.nlm.nih.gov/pubmed/35932306
http://dx.doi.org/10.1007/s00264-022-05524-9
_version_ 1784793514528210944
author Centeno, Christopher J.
Berger, Dustin R.
Money, Brandon T.
Dodson, Ehren
Urbanek, Christopher W.
Steinmetz, Neven J.
author_facet Centeno, Christopher J.
Berger, Dustin R.
Money, Brandon T.
Dodson, Ehren
Urbanek, Christopher W.
Steinmetz, Neven J.
author_sort Centeno, Christopher J.
collection PubMed
description PURPOSE: Knee osteoarthritis (OA) is a common, progressively debilitating joint disease, and the intra-articular injection of autologous bone marrow concentrate (BMC) may offer a minimally invasive method of harnessing the body’s own connective tissue progenitor cells to counteract accompanying degenerative effects of the disease. However, the extent to which the progenitor cell content of BMC influences treatment outcomes is unclear. We sought to determine whether patient-reported outcome measures associated with BMC treatment for knee OA are related to the concentration of progenitor cells provided. METHODS: In the present study, 65 patients (72 knees) underwent treatment for knee OA with autologous BMC and self-reported their outcomes for up to one year using follow-up questionnaires tracking function, pain, and percent improvement. A small fraction of each patient’s BMC sample was reserved for quantification with a haematological analyzer and cryopreserved for subsequent analysis of potential connective tissue progenitor cells using a colony-forming unit fibroblast (CFU-F) assay. RESULTS: Patients reported significant increases in function and overall percent improvement in addition to decreases in pain relative to baseline levels following treatment with autologous BMC that persisted through 12 months. Patients reporting improved outcomes (46 of 72 knees) received BMC injections having higher CFU-F concentrations than non-responding patients (21.1×10(3) ± 12.4×10(3) vs 14.3×10(3) ± 7.0 x10(3) CFU-F per mL). A progenitor cell concentration of 18×10(3) CFU-F per mL of BMC was found to best differentiate responders from non-responders. CONCLUSION: This study provides supportive evidence for using autologous BMC in the minimally invasive treatment of knee OA and suggests that increased progenitor cell content leads to improved treatment outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03011398, 1/7/17 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00264-022-05524-9.
format Online
Article
Text
id pubmed-9492580
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-94925802022-09-23 Percutaneous autologous bone marrow concentrate for knee osteoarthritis: patient-reported outcomes and progenitor cell content Centeno, Christopher J. Berger, Dustin R. Money, Brandon T. Dodson, Ehren Urbanek, Christopher W. Steinmetz, Neven J. Int Orthop Original Paper PURPOSE: Knee osteoarthritis (OA) is a common, progressively debilitating joint disease, and the intra-articular injection of autologous bone marrow concentrate (BMC) may offer a minimally invasive method of harnessing the body’s own connective tissue progenitor cells to counteract accompanying degenerative effects of the disease. However, the extent to which the progenitor cell content of BMC influences treatment outcomes is unclear. We sought to determine whether patient-reported outcome measures associated with BMC treatment for knee OA are related to the concentration of progenitor cells provided. METHODS: In the present study, 65 patients (72 knees) underwent treatment for knee OA with autologous BMC and self-reported their outcomes for up to one year using follow-up questionnaires tracking function, pain, and percent improvement. A small fraction of each patient’s BMC sample was reserved for quantification with a haematological analyzer and cryopreserved for subsequent analysis of potential connective tissue progenitor cells using a colony-forming unit fibroblast (CFU-F) assay. RESULTS: Patients reported significant increases in function and overall percent improvement in addition to decreases in pain relative to baseline levels following treatment with autologous BMC that persisted through 12 months. Patients reporting improved outcomes (46 of 72 knees) received BMC injections having higher CFU-F concentrations than non-responding patients (21.1×10(3) ± 12.4×10(3) vs 14.3×10(3) ± 7.0 x10(3) CFU-F per mL). A progenitor cell concentration of 18×10(3) CFU-F per mL of BMC was found to best differentiate responders from non-responders. CONCLUSION: This study provides supportive evidence for using autologous BMC in the minimally invasive treatment of knee OA and suggests that increased progenitor cell content leads to improved treatment outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03011398, 1/7/17 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00264-022-05524-9. Springer Berlin Heidelberg 2022-08-06 2022-10 /pmc/articles/PMC9492580/ /pubmed/35932306 http://dx.doi.org/10.1007/s00264-022-05524-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Centeno, Christopher J.
Berger, Dustin R.
Money, Brandon T.
Dodson, Ehren
Urbanek, Christopher W.
Steinmetz, Neven J.
Percutaneous autologous bone marrow concentrate for knee osteoarthritis: patient-reported outcomes and progenitor cell content
title Percutaneous autologous bone marrow concentrate for knee osteoarthritis: patient-reported outcomes and progenitor cell content
title_full Percutaneous autologous bone marrow concentrate for knee osteoarthritis: patient-reported outcomes and progenitor cell content
title_fullStr Percutaneous autologous bone marrow concentrate for knee osteoarthritis: patient-reported outcomes and progenitor cell content
title_full_unstemmed Percutaneous autologous bone marrow concentrate for knee osteoarthritis: patient-reported outcomes and progenitor cell content
title_short Percutaneous autologous bone marrow concentrate for knee osteoarthritis: patient-reported outcomes and progenitor cell content
title_sort percutaneous autologous bone marrow concentrate for knee osteoarthritis: patient-reported outcomes and progenitor cell content
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492580/
https://www.ncbi.nlm.nih.gov/pubmed/35932306
http://dx.doi.org/10.1007/s00264-022-05524-9
work_keys_str_mv AT centenochristopherj percutaneousautologousbonemarrowconcentrateforkneeosteoarthritispatientreportedoutcomesandprogenitorcellcontent
AT bergerdustinr percutaneousautologousbonemarrowconcentrateforkneeosteoarthritispatientreportedoutcomesandprogenitorcellcontent
AT moneybrandont percutaneousautologousbonemarrowconcentrateforkneeosteoarthritispatientreportedoutcomesandprogenitorcellcontent
AT dodsonehren percutaneousautologousbonemarrowconcentrateforkneeosteoarthritispatientreportedoutcomesandprogenitorcellcontent
AT urbanekchristopherw percutaneousautologousbonemarrowconcentrateforkneeosteoarthritispatientreportedoutcomesandprogenitorcellcontent
AT steinmetznevenj percutaneousautologousbonemarrowconcentrateforkneeosteoarthritispatientreportedoutcomesandprogenitorcellcontent